Cardiothoracic & vascular anesthesia
Effect of Preoperative Recombinant Human Erythropoietin on the Need for Blood Transfusion and Surgical Outcomes in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis with Trial Sequential Analysis
Study context
- Population
- Adults undergoing elective cardiac surgery
- Comparison
- Preoperative recombinant human erythropoietin (rhEPO) plus standard treatment vs standard treatment only
- Outcome
- Need for and volume of homologous blood transfusion (HBT)
Methodological detailstrial sequential analysis, meta-regression
- Trial sequential analysis
- Meta-regression
Pooled result
As reported in the abstract
rhEPO vs Standard treatmentHedges g (95% CI)
HBT volume; low certainty, moderate reduction
−0.55(−0.79 to −0.32)
- Need for homologous blood transfusion (HBT); very low certainty
- NNT 5.6 (95% CI 3.9–12.5)
Further pooled results
| Outcome | Hedges g (95% CI) | |
|---|---|---|
| ICU LOSModerate certainty, limited reduction | −0.10 (−0.19 to −0.01) | |
| Hospital LOSModerate certainty, limited reduction | −0.13 (−0.25 to −0.02) | |
| −0.3−0.2−0.100.1Difference (linear scale) |
HBT consumption by proportion of females or older patients (meta-regression)
- Studies with a higher proportion of females or older patients showed less benefit of rhEPO in reduced HBT consumption
Safety
| Outcome | NNH (95% CI) |
|---|---|
| MILow certainty for increased risk | 36.1 (17.9–127.4) |
Original publication
Effect of Preoperative Recombinant Human Erythropoietin on the Need for Blood Transfusion and Surgical Outcomes in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. J Cardiothorac Vasc Anesth. Published 18 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →